Girish Mahajan (Editor)

Pefloxacin

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code
  
J01MA03 (WHO)

Metabolism
  
Hepatic

CAS Number
  
70458-92-3

CAS ID
  
70458-92-3

Protein binding
  
20–30%

Biological half-life
  
8.6 hours

Molar mass
  
333.358 g/mol

Bioavailability
  
100%

Pefloxacin

Excretion
  
Mostly renal, also biliary

Pefloxacin is a quinolone drug used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.

Contents

History

Pefloxacin was developed in 1979 and approved in France for human use in 1985.

Licensed uses

  • Uncomplicated gonococcal urethritis in males.
  • Bacterial infections in the gastrointestinal system.
  • Genitourinary tract infections.
  • Gonorrhoeae. however this indication is no longer effective due to bacterial resistance.
  • Pefloxacin has been increasingly used as a veterinary medicine to treat microbial infections.

    Mode of action

    Pefloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, which is an enzyme necessary to separate, replicated DNA, thereby inhibiting cell division.

    Adverse effects

    Tendinitis and rupture, usually of the Achilles tendon, are a class-effects of the fluoroquinolones, most frequently reported with pefloxacin. The estimated risk of tendon damage during pefloxacin therapy has been estimated by the French authorities in 2000 to be 1 case per 23,130 treatment days as compared to ciprofloxacin where it has been estimated to be 1 case per 779,600.

    References

    Pefloxacin Wikipedia